{"id":3264,"date":"2025-10-06T05:52:40","date_gmt":"2025-10-06T05:52:40","guid":{"rendered":"https:\/\/genoks.com.tr\/docs\/genoxhere-prostate-en\/"},"modified":"2026-05-02T05:14:17","modified_gmt":"2026-05-02T05:14:17","password":"","slug":"genoxhere-prostate-en","status":"publish","type":"docs","link":"https:\/\/genoks.com.tr\/en\/docs\/genoxhere-prostate-en\/","title":{"rendered":"Prostate Cancer and GenoXhere Prostate Panel"},"content":{"rendered":"

<\/p>\n

Prostate Cancer and the GenoXhere Prostate Panel.<\/strong> Hereditary prostate cancer accounts for ~10% of cases. Key predisposition genes include BRCA2 (highest risk, ~14-30% lifetime), HOXB13 G84E, BRCA1, ATM, CHEK2, MMR genes (Lynch). NCCN recommends germline testing for metastatic, high-risk localized, and family-history positive prostate cancer. Test results guide PARP inhibitor (olaparib, talazoparib) eligibility and cascade testing of relatives. Reporting: 4-6 weeks.<\/p>\n

<\/p>\n

Genetik ge\u00e7i\u015fli prostat kanseri, prostat kanserinin kal\u0131t\u0131msal yollarla ge\u00e7ebilece\u011fi bir durumdur. Prostat kanseri, prostat bezindeki h\u00fccrelerin kontrols\u00fcz b\u00fcy\u00fcmesi sonucu olu\u015fan bir kanser t\u00fcr\u00fcd\u00fcr. Genetik ge\u00e7i\u015fli prostat kanseri, ailesinde daha \u00f6nce prostat kanseri olan ki\u015filerde daha s\u0131k g\u00f6r\u00fcl\u00fcr ve bu durum, bir\u00e7ok farkl\u0131 genetik fakt\u00f6rden kaynaklanabilir.<\/p>\n

Baz\u0131 ara\u015ft\u0131rmalar, BRCA1 ve BRCA2 gibi genlerdeki mutasyonlar\u0131n, erkeklerde prostat kanserinin g\u00f6r\u00fclme s\u0131kl\u0131\u011f\u0131n\u0131 art\u0131rd\u0131\u011f\u0131n\u0131 g\u00f6stermi\u015ftir. Bu genler, normalde meme kanseri ve yumurtal\u0131k kanseri riskini art\u0131ran genlerdir. Ancak, erkeklerde de bu genlerdeki mutasyonlar prostat kanseri riskini art\u0131rabilir.<\/p>\n

Genetik ge\u00e7i\u015fli prostat kanseri, erken ya\u015fta (50 ya\u015f\u0131n alt\u0131nda) prostat kanseri olan erkeklerde daha yayg\u0131nd\u0131r. Bu nedenle, ailesinde prostat kanseri \u00f6yk\u00fcs\u00fc olan ki\u015filerin, prostat kanseri i\u00e7in erken tarama yapmalar\u0131 \u00f6nerilir.<\/p>\n

Tedavi, prostat kanserinin t\u00fcr\u00fcne ve yay\u0131l\u0131m\u0131na ba\u011fl\u0131 olarak de\u011fi\u015febilir. Tedavi se\u00e7enekleri aras\u0131nda ameliyat, radyasyon tedavisi, hormon tedavisi ve kemoterapi yer al\u0131r. Ancak, genetik ge\u00e7i\u015fli prostat kanseri olan ki\u015filerde, prostat kanseri daha agresif olabilece\u011finden, tedavi se\u00e7enekleri ve takip daha dikkatli bir \u015fekilde yap\u0131lmal\u0131d\u0131r.<\/p>\n\n\n\n\n\n\n\n\n
GEN :<\/strong><\/td>\nATM | BRCA1 | BRCA2 | CHEK2 | EPCAM | HOXB13 | MLH1 | MSH2 | MSH6 | NBN | PMS2 | TP53<\/td>\n<\/tr>\n
Y\u00f6ntem :<\/strong><\/td>\nNGS<\/td>\n<\/tr>\n
Raporlama S\u00fcresi :<\/strong><\/td>\n8 Hafta (+\/- 2 Hafta)<\/td>\n<\/tr>\n
Prenatal\/ Postnatal:<\/strong><\/strong><\/td>\nPostnatal<\/td>\n<\/tr>\n
Gerekli Numune<\/strong>:<\/td>\nEDTA’l\u0131 Kan (2-4 ml)<\/td>\n<\/tr>\n
Saklama \/ Ta\u015f\u0131ma S\u0131cakl\u0131\u011f\u0131:<\/strong><\/td>\n+ 4C\u00b0\/ + 24C\u00b0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

T\u00fcm genetik testlerimiz “Hasta Onam Formu”<\/strong> ve “KVKK Formu”<\/strong>nun imzalanmas\u0131n\u0131n ard\u0131ndan \u00e7al\u0131\u015f\u0131lmaya ba\u015flan\u0131r.<\/p>\n

\n

Detayl\u0131 Bilgi Almak \u0130\u00e7in Bize Mesaj Atabilirsiniz.<\/strong><\/p>\n\n\n\n
[contact-form-7 id=”710″ title=”genetik ba\u015fvuru”]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Genoks Genetik Hastal\u0131klar De\u011ferlendirme Merkezi T.C. Sa\u011fl\u0131k Bankanl\u0131\u011f\u0131nca denetlenen ve GHDM-SM\/06.15\/01 ruhsat numaras\u0131 ile hizmet veren sa\u011fl\u0131k kurulu\u015fudur. genoks.com.tr web sayfas\u0131nda bulunan bilgiler, genetik de\u011ferlendirme ve\/veya tan\u0131-te\u015fhis ama\u00e7l\u0131 kullan\u0131lmamal\u0131d\u0131r. T\u00fcm i\u00e7erikler bilgilendirme ama\u00e7l\u0131d\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"

Prostate Cancer and the GenoXhere Prostate Panel. Hereditary prostate cancer accounts for ~10% of cases. Key predisposition genes include BRCA2 (highest risk, ~14-30% lifetime), HOXB13 G84E, BRCA1, ATM, CHEK2, MMR genes (Lynch). NCCN recommends germline testing for metastatic, high-risk localized, [\u2026]<\/span><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"doc_category":[204],"doc_tag":[],"class_list":["post-3264","docs","type-docs","status-publish","hentry","doc_category-genoks-gdhm-genetic-tests"],"aioseo_notices":[],"year_month":"2026-05","word_count":409,"total_views":0,"reactions":{"happy":0,"normal":0,"sad":0},"author_info":{"name":"admin","author_nicename":"admin","author_url":"https:\/\/genoks.com.tr\/en\/author\/admin\/"},"doc_category_info":[{"term_name":"Genoks GDHM Genetic Tests","term_url":"https:\/\/genoks.com.tr\/en\/docs-category\/genoks-gdhm-genetic-tests\/"}],"doc_tag_info":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t